Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Trelagliptin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 20/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.69 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trelagliptin SCHEMBL19534887 | 1.00 | DPP4 (1.00) | DPP4OPRM1OPRK1CYP1A2CYP3A4 | |
| Trelagliptin SCHEMBL878010 | 1.00 | DPP4 (1.00) | DPP4OPRM1OPRK1CYP1A2CYP3A4 | |
| Trelagliptin SCHEMBL29364762 | 1.00 | DPP4 (1.00) | DPP4OPRM1OPRK1CYP1A2CYP3A4 | |
| Trelagliptin SCHEMBL28390472 | 1.00 | DPP4 (1.00) | DPP4OPRM1OPRK1CYP1A2CYP3A4 | |
| Trelagliptin SCHEMBL175727 | 0.94 | DPP4 (1.00) | DPP4OPRM1OPRK1CYP1A2CYP3A4 | |
| Trelagliptin SCHEMBL175726 | 0.94 | DPP4 (1.00) | DPP4OPRM1OPRK1CYP1A2CYP3A4 | |
| Trelagliptin SCHEMBL29349599 | 0.94 | DPP4 (1.00) | DPP4OPRM1OPRK1CYP1A2CYP3A4 | |
| SCHEMBL27964065 | 0.87 | DPP4 (0.86) | DPP4OPRM1OPRK1CYP1A2CYP3A4 | |
| SCHEMBL28151193 | 0.87 | DPP4 (0.86) | DPP4OPRM1OPRK1CYP1A2CYP3A4 | |
| SCHEMBL18381012 | 0.86 | DPP4 (0.79) | DPP4OPRM1OPRK1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110950840-B | Preparation method of trelagliptin succinate | 江苏天和制药有限公司 | 2022-03-15 | — | — | CN | disclosed |
| CN-110950840-A | Preparation method of trelagliptin succinate | 江苏天和制药有限公司 | 2020-04-03 | — | — | CN | disclosed |
| US-9809569-B2 | Process for producing heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-11-07 | — | — | US | disclosed |
| EP-3083580-A1 | A PROCESS FOR PREPARATION OF TRELAGLIPTIN SUCCINATE | Harman Finochem Limited (IN) | 2016-10-26 | — | — | EP | disclosed |
| CN-105017161-A | Compound, and preparation method and applications thereof | NANJING BIODEALPHARM CO LTD | 2015-11-04 | — | — | CN | disclosed |
| WO-2015092805-A1 | A PROCESS FOR PREPARATION OF TRELAGLIPTIN SUCCINATE | HARMAN FINOCHEM LIMITED (IN) | 2015-06-25 | — | — | WO | disclosed |
| CN-103539791-A | Modulators of the GPR119 receptor and the treatment of disorders related thereto | ARENA PHARM INC | 2014-01-29 | — | — | CN | disclosed |
| EP-2102185-B1 | POLYMORPHS OF SUCCINATE SALT OF 2-[6-(3-AMINO-PIPERIDIN-1-YL)-3-METHYL-2,4-DIOXO-3,4-DIHYDRO-2H-PYRIMIDIN-1-YLMETHY]-4-FLUOR-BENZONITRILE AND METHODS OF USE THEREFOR | TAKEDA PHARMACEUTICAL (JP) | 2012-08-15 | — | — | EP | disclosed |
| US-20120197018-A1 | POLYMORPHS OF SUCCINATE SALT OF 2-[6-(3-AMINO-PIPERIDIN-1-YL)-3-METHYL-2,4-DIOXO-3,4-DIHYDRO-2H-PYRIMIDIN-1-YLMETHY]-4-FLUOR-BENZONITRILE AND METHODS OF USE THEREFOR | KELLY RON C (US) | 2012-08-02 | — | — | US | disclosed |
| US-8084605-B2 | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor | SSCI, INC.AN APTUIT COMPANY | 2011-12-27 | — | — | US | disclosed |
| EP-2102185-A1 | POLYMORPHS OF SUCCINATE SALT OF 2-[6-(3-AMINO-PIPERIDIN-1-YL)-3-METHYL-2,4-DIOXO-3,4-DIHYDRO-2H-PYRIMIDIN-1-YLMETHY]-4-FLUOR-BENZONITRILE AND METHODS OF USE THEREFOR | Takeda Pharmaceutical Company Limited (JP) | 2009-09-23 | — | — | EP | disclosed |
| US-20080280931-A1 | POLYMORPHS OF SUCCINATE SALT OF 2-[6-(3-AMINO-PIPERIDIN-1-YL)-3-METHYL-2,4-DIOXO-3,4-DIHYDRO-2H-PYRIMIDIN-1-YLMETHY]-4-FLUOR-BENZONITRILE AND METHODS OF USE THEREFOR | SSCI, INC.AN APTUIT COMPANY | 2008-11-13 | — | — | US | disclosed |
| US-20080227798-A1 | POLYMORPHS OF SUCCINATE SALT OF 2-[6-(3-AMINO-PIPERIDIN-1-YL)-3-METHYL-2,4-DIOXO-3,4-DIHYDRO-2H-PYRIMIDIN-1-YLMETHY]-4-FLUOR-BENZONITRILE AND METHODS OF USE THEREFOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-18 | — | — | US | disclosed |
| WO-2008067465-A1 | POLYMORPHS OF SUCCINATE SALT OF 2-[6-(3-AMINO-PIPERIDIN-1-YL)-3-METHYL-2,4-DIOXO-3,4-DIHYDRO-2H-PYRIMIDIN-1-YLMETHY]-4-FLUOR-BENZONITRILE AND METHODS OF USE THEREFOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227798-A1 | POLYMORPHS OF SUCCINATE SALT OF 2-[6-(3-AMINO-PIPERIDIN-1-YL)-3-METHYL-2,4-DIOXO-3,4-DIHYDRO-2H-PYRIMIDIN-1-YLMETHY]-4-FLUOR-BENZONITRILE AND METHODS OF USE THEREFOR | SUCNR1, SLC16A1, HADHB | DPP4 703/4885OPRM1 1732/4885OPRK1 1505/4885 |
| US-20120197018-A1 | POLYMORPHS OF SUCCINATE SALT OF 2-[6-(3-AMINO-PIPERIDIN-1-YL)-3-METHYL-2,4-DIOXO-3,4-DIHYDRO-2H-PYRIMIDIN-1-YLMETHY]-4-FLUOR-BENZONITRILE AND METHODS OF USE THEREFOR | SUCNR1, SLC16A1, HADHB | DPP4 703/4885OPRM1 1732/4885OPRK1 1505/4885 |
| US-20080280931-A1 | POLYMORPHS OF SUCCINATE SALT OF 2-[6-(3-AMINO-PIPERIDIN-1-YL)-3-METHYL-2,4-DIOXO-3,4-DIHYDRO-2H-PYRIMIDIN-1-YLMETHY]-4-FLUOR-BENZONITRILE AND METHODS OF USE THEREFOR | SUCNR1, SLC16A1, HADHB | DPP4 703/4885OPRM1 1732/4885OPRK1 1505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.